Taken together, these data indicate that the radiocobalt-labelled DOTA-ZEGFR:2377 demonstrated the best tumour-to-non-tumour ratios among all pre-clinically tested affibody-based agents for imaging of EGFR. The gene discussed is EGFR; the disease is neoplasm.